Rituxan® Immunotherapy and Zevalin® Radioimmunotherapy in the Treatment of Non-Hodgkin's Lymphoma

Publisher： Bentham Science Publishers

E-ISSN： 1873-4316|4|4|221-238

ISSN： 1389-2010

Source： Current Pharmaceutical Biotechnology, Vol.4, Iss.4, 2003-08, pp. : 221-238

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Zevalin TM: 90 Yttrium Labeled Anti-CD20 (Ibritumomab Tiuxetan), a New Treatment for Non-Hodgkin's Lymphoma

By  

Current Pharmaceutical Biotechnology, Vol. 2, Iss. 4, 2001-12 ,pp. : 341-349

Bentham Science Publishers

Access to resources Recommend Favorite

Radioimmunotherapy of Non-Hodgkin's Lymphomas

By  

Current Drug Targets, Vol. 7, Iss. 10, 2006-10 ,pp. : 1293-1300

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma

By Jamal-Hanjani Mariam   Pettengell Ruth  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 11, 2011-11 ,pp. : 1441-1448

Informa Healthcare

Access to resources Recommend Favorite

Pixantrone for the treatment of aggressive non-Hodgkin lymphoma

By Mukherji Deborah   Pettengell Ruth  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 11, 2010-08 ,pp. : 1915-1923

Informa Healthcare

Access to resources Recommend Favorite

Monoclonal Antibodies in the Treatment of Non-Hodgkin's Lymphoma

By Fanale Michelle A.   Younes Anas  

Drugs, Vol. 67, Iss. 3, 2007-01 ,pp. : 333-350

Adis International

Access to resources Recommend Favorite